X4 Pharmaceuticals Files 8-K: Material Agreement, Financials

Ticker: XFOR · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1501697

X4 Pharmaceuticals, Inc 8-K Filing Summary
FieldDetail
CompanyX4 Pharmaceuticals, Inc (XFOR)
Form Type8-K
Filed DateJan 13, 2025
Risk Levelmedium
Pages4
Reading Time5 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: material-agreement, financials, disclosure

TL;DR

X4 Pharma dropped an 8-K on Jan 13th - new material agreement, financials included.

AI Summary

On January 13, 2025, X4 Pharmaceuticals, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes Regulation FD disclosures and financial statements/exhibits. The company, formerly known as Arsanis, Inc., is incorporated in Delaware and headquartered in Boston, MA.

Why It Matters

This 8-K filing signals a significant development for X4 Pharmaceuticals, likely involving a new contract or partnership that could impact its business operations and financial standing.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, and the inclusion of financial statements suggests ongoing financial activity that warrants attention.

Key Numbers

  • 001-38295 — Commission File Number (Identifies the company's SEC filings)
  • 27-3181608 — IRS Employer Identification No. (Company's tax identification number)

Key Players & Entities

  • X4 Pharmaceuticals, Inc. (company) — Registrant
  • Arsanis, Inc. (company) — Former company name
  • January 13, 2025 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of incorporation
  • Boston, Massachusetts (location) — Principal executive offices
  • 001-38295 (identifier) — Commission File Number
  • 27-3181608 (identifier) — IRS Employer Identification No.

FAQ

What is the nature of the material definitive agreement filed on January 13, 2025?

The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the excerpt.

What other items are included in this 8-K filing besides the material agreement?

The filing also includes Regulation FD Disclosure and Financial Statements and Exhibits.

When was X4 Pharmaceuticals, Inc. incorporated?

X4 Pharmaceuticals, Inc. was incorporated in Delaware.

What was the previous name of X4 Pharmaceuticals, Inc.?

The company was formerly known as Arsanis, Inc.

Where are X4 Pharmaceuticals, Inc.'s principal executive offices located?

The principal executive offices are located at 61 North Beacon Street, 4th Floor, Boston, Massachusetts 02134.

Filing Stats: 1,227 words · 5 min read · ~4 pages · Grade level 13.7 · Accepted 2025-01-13 07:50:34

Key Financial Figures

  • $0.001 — ich registered Common Stock, par value $0.001 per share XFOR The Nasdaq Stock Market

Filing Documents

01 Entry Into a Material Definitive Agreement

Item 1.01 Entry Into a Material Definitive Agreement. On January 13, 2025, X4 Pharmaceuticals, Inc. (the "Company" or "X4") entered into a License and Supply Agreement (the "Agreement") with Norgine Pharma UK Limited ("Norgine"), pursuant to which Norgine is granted an exclusive license to (i) distribute, market and sell the Company's product mavorixafor (marketed by X4 as XOLREMDI in the United States) for all indications in the European Economic Area, Switzerland, the United Kingdom, Australia and New Zealand (collectively, the "Territory"), following regulatory approval. Additionally, Norgine was granted a co-exclusive license to manufacture mavorixafor for the Territory within the Field (as defined in the Agreement). The Company retains all rights to mavorixafor outside the Territory and specific reserved rights within the Territory. Norgine may grant sublicenses to its affiliates and certain third parties subject to the terms of the Agreement, except that it may not sublicense the commercial rights granted under the Agreement for certain countries without X4's explicit consent. Pursuant to the terms of the Agreement, the Company shall receive the following payments from Norgine: (i) an upfront payment in the amount of 28.5 million, (ii) up to 226 million upon the achievement of certain regulatory, commercial and sales milestones, and (iii) escalating double-digit royalties of up to mid-twenties on any future net sales in the Territory. The tiered royalty payments are subject to royalty stacking, and to a material reduction on a country-by-country basis if a generic version of mavorixafor becomes available in the applicable country. X4 and Norgine will collaborate closely on regulatory filings, with X4 continuing to be responsible for the ongoing global, pivotal Phase 3 4WARD clinical trial evaluating mavorixafor in chronic neuropathy. Norgine will be responsible for all market access and commercialization activities and will eventually hold all marketing au

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 13, 2025, the Company issued a press release announcing the Agreement. A copy of the press release is filed as Exhibit 99.1 hereto. The Company also posted an updated corporate presentation on the Company's website attached as Exhibit 99.2 hereto. The information contained in this Item 7.01, including Exhibit 99.1 and 99.2 filed herewith, is being furnished and shall not be deemed to be filed for the purposes of Section 18 of the Exchange Act, or incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless such subsequent filing specifically references this Form 8-K.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release, dated January 13, 2025 99.2 Corporate Presentation, dated January 13, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. X4 PHARMACEUTICALS, INC. Date: January 13, 2025 By: /s/ Adam Mostafa Adam Mostafa Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.